Perceptive Advisors is a venture capital firm that primarily invests in early-stage life sciences companies, including those in biotechnology, pharmaceuticals, and health tech sectors. Their strategy involves leading or co-leading Series A financings, with a focus on advancing differentiated technologies from preclinical stages through clinical proof-of-concept.
54% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $120.4M (across 48 rounds with reported amounts).
Portfolio
48
Fund Size
$8.5B
Top Stage
Series B
Last 12 Mo
7
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
48 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| GGiant | Seed | $8M | Feb 2026 |
 Novig | Series B | $75M | Feb 2026 |
 Talkiatry | Series D | $210M | Feb 2026 |
 Dispatch | Series A | $18M | Sep 2025 |
 InstaLILY AI | Series A | $25M | Aug 2025 |
| Novig | Series A | $18M | Aug 2025 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
| RRAPT Therapeutics, Inc. | Series D | $150M | Dec 2024 |
 Axonis Therapeutics | Series A | $115M | Oct 2024 |
| IInventiva | Unknown | $410M | Oct 2024 |
| Talkiatry | Series C | $130M | Jun 2024 |
 Insightec | Growth | $150M | Jun 2024 |
 Pheon Therapeutics | Series B | $120M | May 2024 |
| RRapport Therapeutics | Series B | $150M | Aug 2023 |
 Kindbody | Growth | $100M | Mar 2023 |
 Omada Health | Series E | $192M | Feb 2022 |
 Beta Bionics, Inc. | Series C | $57M | Feb 2022 |
 Freenome | Series D | $300M | Dec 2021 |
 Emulate Inc. | Series E | $82M | Sep 2021 |
 Bridge to Life | Series A | $56M | Aug 2021 |
| Kindbody | Series C | $62M | Jun 2021 |
 Cue Health | Growth | $235M | May 2021 |
 Affinia Therapeutics | Series B | $110M | May 2021 |
 AbSci | Growth | $125M | Mar 2021 |
 Neuron23 | Series B | $113.5M | Dec 2020 |
Page 1 of 2
Top Co-Investors
RA Capital Management10 shared
GV (Google Ventures)8 shared
Redmile Group6 shared
Andreessen Horowitz6 shared
Cormorant Asset Management5 shared
Casdin Capital5 shared
T. Rowe Price Associates, Inc.4 shared
Logos Capital4 shared
ArrowMark Partners4 shared
Avidity Partners4 shared
NEA (New Enterprise Associates)4 shared
OrbiMed4 shared
Wellington Management4 shared
Roche Venture Fund4 shared
BVF Partners LP4 shared
Deep Track Capital4 shared
RTW Investments4 shared
Sofinnova Partners3 shared
Janus Henderson Investors3 shared
Last updated: 12 April 2026